We’re excited to share positive topline Phase 3 data from FORTIFY, our study of small molecule, BBP-418, in development for individuals with LGMD2I/R9. Learn more: https://t.co/mmYiJJ1xTp #LGMD $BBIO
Proud moment: Dr. Neil Kumar, CEO & Founder of BridgeBio, is @PM360online’s 2025 Trailblazer CEO of the Year. We appreciate your ongoing commitment to putting patients first and thank you to PM360 for the recognition!
from @farnamstreet newsletter:
"Most arguments are ego competitions disguised as truth-seeking.
Learning to say 'you're probably right' will save you a lot of time and energy."
They are probably right.
My friend Dr. Robert Greene gave an awesome TED talk on the huge positive impact of genetic sequencing for all new borns. He has dedicated himself to making this case through deep academic research. Universal genetic sequencing is precursor of precision health at scale! @RobertCGreen , @Genomes2People
https://t.co/x3r5gQTEr1 via @TEDTalks
I’ve been privileged to watch behind the scenes as Farid, Nasha, and David have been climbing the startup mountain. This is the one of many milestones ahead of this ambitious, and necessary, vision to serve patient communities everywhere! #RareDisease
We've secured $30M in funding from @8vc@transformcptl, Headline to use AI to transform consumer healthcare, starting in rare disease. https://t.co/6iNEDNjFv8
📊 Centralized records 🧠 Personalized AI Advocate 🔬 Research participation
Build with us: https://t.co/0CsppLLhVy
Remarkable start to patient impact for Attruby. This medicine had its first prescription 90 minutes after its Friday afternoon approval on 11/22/24. 6 weeks later we are excited to share that 430 prescriptions for Attruby have been written. @BridgeBioPharma is gonna have a huge impact for patients in 2025! #JPM #jpm2025
So pumped for Connor, Andrew, and team. Fun fact: Speak is a standout company that @andrewchen and I invested in together when we ran our angel fund together back in 2017! I can't wait to see the next decade unfold for Speak.
1/ Excited to announce Speak has raised a $78m Series C from @Accel at a $1b valuation!
It' a huge milestone for us and continued validation of our founding idea: AI would fundamentally transform learning. 8 years later, we’re well on our way and believe this more than ever. 🧵
Andrew, Connor, and the Speak team have been focusing on AI speech to speech since 2017 when @andrewchen and I first invested in them. It is amazing to see where they’ve taken the product and to dream of everything to come. #openai
We’ve been working closely with OpenAI for the past few months to test the new Realtime API. I’m excited to share some thoughts on the best way to productize speech-to-speech for language learning, and announce the first thing we’ve built here, Live Roleplays. 🧵
I’ve started a new company - Unblocked
We’re eliminating the countless hours developers spend in meetings, dealing with interruptions and searching for documents as they look for answers to questions about their codebase.
The details and motivation here: https://t.co/XZd07vhGCP
@andrewchen explains one of the best career questions you can ask yourself!
The Next Next Job, a framework for making big career decisions - https://t.co/d11wtPHfss